Fibulin-3 as a biomarker of response to treatment in malignant mesothelioma

1. Berry M. Mesothelioma incidence and community asbestos exposure. Environ Res 1997; 75: 34-40.10.1006/enrs.1997.3770Search in Google Scholar

2. Iwatsubo Y, Pairon JC, Boutin C, Menard O, Massin N, Caillaud D, et al. Pleural mesothelioma: dose-response relation at low levels of asbestos exposure in a French population-based case-control study. Am J Epidemiol 1998; 148: 133-42.10.1093/oxfordjournals.aje.a009616Search in Google Scholar

3. Howel D, Gibbs A, Arblaster L, Swinburne L, Schweiger M, Renvoize E, et al. Mineral fibre analysis and routes of exposure to asbestos in the development of mesothelioma in an English region. Occup Environ Med 1999; 56: 51-8.10.1136/oem.56.1.51Search in Google Scholar

4. Agudo A, González CA, Bleda MJ, Ramirez J, Hernandez S, Lopez F, et al. Occupation and risk of malignant pleural mesothelioma: a case-control study in Spain. Am J Ind Med 2000; 37: 159-68.10.1002/(SICI)1097-0274(200002)37:2<159::AID-AJIM1>3.0.CO;2-0Search in Google Scholar

5. Magnani C, Dalmasso P, Biggeri A, Ivaldi C, Mirabelli D, Terracini B. Increased risk of malignant mesothelioma of the pleura after residential or domestic exposure to asbestos: a case-control study in Casale Monferrato, Italy. Environ Health Perspect 2001; 109: 915-9.10.1289/ehp.01109915Search in Google Scholar

6. Zellos L, Christiani DC. Epidemiology, biologic behaviour, and natural history of mesothelioma. Thorac Surg Clin 2004; 14: 469-77.10.1016/j.thorsurg.2004.06.011Search in Google Scholar

7. Pan XL, Day HW, Wang W, Beckett LA, Schenker MB. Residential proximity to naturally occurring asbestos and mesothelioma risk in California. Am J Respir Crit Care Med 2005; 172: 1019-25.10.1164/rccm.200412-1731OCSearch in Google Scholar

8. Maule MM, Magnani C, Dalmasso P. Modeling mesothelioma risk associated with environmental asbestos exposure. Environ Health Perspect 2007; 115: 1066-71.10.1289/ehp.9900Search in Google Scholar

9. Robinson BW, Lake RA. Advances in malignant mesothelioma. N Engl J Med 2005; 353: 1591-603.10.1056/NEJMra050152Search in Google Scholar

10. Kovac V, Zwitter M, Zagar T. Improved survival after introduction of chemotherapy for malignant pleural mesothelioma in Slovenia: population-based survey of 444 patients. Radiol Oncol 2012; 46: 136-44.10.2478/v10019-012-0032-0Search in Google Scholar

11. Hollevoet K, Reitsma JB, Creaney J, Grigoriu BD, Robinson BW, Scherpereel A, et al. Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis. J Clin Oncol 2012; 30: 1541-9.10.1200/JCO.2011.39.6671338312222412141Search in Google Scholar

12. Franko A, Dolzan V, Kovac V, Arneric N, Dodic-Fikfak M. Soluble mesothelin-related peptides levels in patients with malignant mesothelioma. Dis Markers 2012; 32: 123-31.10.1155/2012/430689Search in Google Scholar

13. Pass HI, Levin SM, Harbut MR, Melamed J, Chiriboga L, Donington J, et al. Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma. N Engl J Med 2012; 367: 1417-27.10.1056/NEJMoa1115050376121723050525Search in Google Scholar

14. Timpl R, Sasaki T, Kostka G, Chu ML. Fibulins: a versatile family of extracellular matrix proteins. Nat Rev Mol Cell Biol 2003; 4: 479-89.10.1038/nrm113012778127Search in Google Scholar

15. Argraves WS, Greene LM, Cooley MA, Gallagher WM. Fibulins: physiological and disease perspectives. EMBO Rep 2003; 4: 1127-31.10.1038/sj.embor.7400033132642514647206Search in Google Scholar

16. Zhang Y, Marmorstein LY. Focus on molecules: fibulin-3 (EFEMP1). Exp Eye Res 2010; 90: 374-5.10.1016/j.exer.2009.09.018289654619799900Search in Google Scholar

17. Kim IG, Kim SY, Choi SI, Lee JH, Kim KC, Cho EW. Fibulin-3-mediated inhibition of epithelial-to-mesenchymal transition and self-renewal of ALDH+ lung cancer stem cells through IGF1R signaling. Oncogene 2014; 33: 3908-17.10.1038/onc.2013.37324013232Search in Google Scholar

18. Kobayashi N, Kostka G, Garbe JH, Keene DR, Bachinger HP, Hanisch FG, et al. A comparative analysis of the fibulin protein family. Biochemical characterization, binding interactions, and tissue localization. J Biol Chem 2007; 282: 11805-16.10.1074/jbc.M61102920017324935Search in Google Scholar

19. Yue W, Dacic S, Sun Q, Landreneau R, Guo M, Zhou W, et al. Frequent inactivation of RAMP2, EFEMP1 and Dutt1 in lung cancer by promoter hypermethylation. Clin Cancer Res 2007; 13: 4336-44.10.1158/1078-0432.CCR-07-001517671114Search in Google Scholar

20. Xu S, Yang Y, Sun YB, Wang HY, Sun CB, Zhang X. Role of fibulin-3 in lung cancer: in vivo and in vitro analyses. Oncol Rep 2014; 31: 79-86.10.3892/or.2013.279924142183Search in Google Scholar

21. Sadr-Nabavi A, Ramser J, Volkmann J, Naehrig J, Wiesmann F, Betz B, et al. Decreased expression of angiogenesis antagonist EFEMP1 in sporadic breast cancer is caused by aberrant promoter methylation and points to an impact of EFEMP1 as molecular biomarker. Int J Cancer 2009; 124: 1727-35.10.1002/ijc.2410819115204Search in Google Scholar

22. Nomoto S, Kanda M, Okamura Y, Nishikawa Y, Qiyong L, Fujii T, et al. Epidermal growth factor-containing fibulin-like extracellular matrix protein 1, EFEMP1, a novel tumor-suppressor gene detected in hepatocellular carcinoma using double combination array analysis. Ann Surg Oncol 2010; 17: 923-32.10.1245/s10434-009-0790-019898900Search in Google Scholar

23. Hu B, Thirtamara-Rajamani KK, Sim H, Viapiano MS. Fibulin-3 is uniquely upregulated in malignant gliomas and promotes tumor cell motility and invasion. Mol Cancer Res 2009; 7: 1756-70.10.1158/1541-7786.MCR-09-0207389609619887559Search in Google Scholar

24. En-lin S, Sheng-guo C, Hua-qiao W. The expression of EFEMP1 in cervical carcinoma and its relationship with prognosis. Gynecol Oncol 2010; 117: 417-22.10.1016/j.ygyno.2009.12.01620378157Search in Google Scholar

25. Seeliger H, Camaj P, Ischenko I, Kleespies A, De Toni EN, Thieme SE, et al. EFEMP1 expression promotes in vivo tumor growth in human pancreatic adenocarcinoma. Mol Cancer Res 2009; 7: 189-98.10.1158/1541-7786.MCR-08-013219208748Search in Google Scholar

26. Creaney J, Dick IM, Meniawy TM, Leong SL, Leon JS, Demelker Y, et al. Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma. Thorax 2014; 69: 895-902.10.1136/thoraxjnl-2014-205205417412425037982Search in Google Scholar

27. UICC International Union Against Cancer. Pleurak mesothelioma. In: Sobin LH, Gospodarowicz MK, Wittekind C, editors. TNM classification of malignant tumours, 7^th edition. Chichester: Wiley-Blackwell; 2009. p. 147-50.Search in Google Scholar

28. Byrne MJ, Nowak AK. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol 2004; 15: 257-60.10.1093/annonc/mdh05914760119Search in Google Scholar

29. Podobnik J, Kocijancic I, Kovac V, Sersa I. 3T MRI in evaluation of asbestos-related thoracic diseases - preliminary results. Radiol Oncol 2010; 44: 92-6.10.2478/v10019-010-0027-7342368522933897Search in Google Scholar

30. Zwitter M, Stanic K, Rajer M, Kern I, Vrankar M, Edelbaher N, et al. Intercalated chemotherapy and erlotinib for advanced NSCLC: high proportion of complete remissions and prolonged progression-free survival among patients with EGFR activating mutations. Radiol Oncol 2014; 48: 361-8.10.2478/raon-2014-0038423055625435849Search in Google Scholar

31. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003; 21: 2636-44.10.1200/JCO.2003.11.13612860938Search in Google Scholar

32. Goricar K, Kovac V, Dolzan V. Polymorphisms in folate pathway and pemetrexed treatment outcome in patients with malignant pleural mesothelioma. Radiol Oncol 2014; 48: 163-72.10.2478/raon-2013-0086407803524991206Search in Google Scholar

33. Lee CW, Murray N, Anderson H, Rao SC, Bishop W. Outcomes with first-line platinum-based combination chemotherapy for malignant pleural mesothelioma: A review of practice in British Columbia. Lung Cancer 2009; 64: 308-13.10.1016/j.lungcan.2008.09.00819004520Search in Google Scholar

34. Kovac V, Zwitter M, Rajer M, Marin A, Debeljak A, Smrdel U, et al. A phase II trial of low-dose gemcitabine in prolonged infusion and cisplatin for malignant pleural mesothelioma. Anticancer Drugs 2012; 23: 230-8.10.1097/CAD.0b013e32834d7a1c22027538Search in Google Scholar

35. Ferris BG. Epidemiology Standardization Project (American Thoracic Society). Am Rev Respir Dis 1978; 118: 1-20.Search in Google Scholar

36. Dodic Fikfak M, Kriebel D, Quinn MM, Eisen EA, Wegman DH. A case control study of lung cancer and exposure to chrysotile and amphibole at a Slovenian asbestos-cement plant. Ann Occup Hyg 2007; 51: 261-8.Search in Google Scholar